Showing 6371-6380 of 9134 results for "".
- Gene Sequencing May Quantify Risk of Skin Cancer Long Before Damage is Visiblehttps://practicaldermatology.com/news/gene-sequencing-may-quantify-risk-of-skin-cancer-long-before-damage-is-visible/2460644/New research sheds light on the carcinogenic effect of exposure to ultraviolet (UV) radiation, laying the groundwork for improvements in skin cancer risk stratification and prevention. In a study published&nbs
- Soliton Appoints Sean J. Shapiro as Vice President of Saleshttps://practicaldermatology.com/news/soliton-appoints-sean-j-shapiro-as-vice-president-of-sales/2460643/Sean J. Shapiro is Soliton, Inc’s New Vice President of Sales, effective January 1, 2021. "We are very excited to have Sean join our team during this pivotal time for the company as we anticipate clearance of our 510(k) application for cellulite reduction duri
- Three Dermal Filler Patients Had Adverse Reactions to the Moderna COVID-19 Vaccinehttps://practicaldermatology.com/news/three-filler-patients-had-adverse-reactions-to-the-moderna-covid-19-vaccine/2460642/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://practicaldermatology.com/news/ajinomoto-bio-pharma-services-and-revance-therapeutics-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2460641/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.
- DermOQ Oxygen Lab Completes Purchase of ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://practicaldermatology.com/news/dermoq-oxygen-lab-completes-purchase-of-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2460640/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- Aerolase Introduces Skin of Color Forumhttps://practicaldermatology.com/news/aerolase-introduces-skin-of-color-forum/2460639/Aerolase Corp. is launching a Skin of Color Forum (SOCF). "This Forum is much needed and transformative. It's been rewarding to work alongside Aerolase to shape its leadership in advancing skin of color dermatology," sa
- Positive Topline Data from Phase 2b Study of Roflumilast Foam for Scalp and Body Psoriasishttps://practicaldermatology.com/news/positive-topline-data-from-phase-2b-study-of-roflumilast-foam-for-scalp-and-body-psoriasis/2460633/Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, shared positive top line data from a Phase 2b clinical trial evaluating ARQ-
- Almirall's Klisyri Gets FDA Approval for AKshttps://practicaldermatology.com/news/almiralls-klisyri-gets-fda-approval-for-aks/2460632/Almirall is expected to launch Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) of the face or scalp in the first quarter of 2021, after receiving FDA approval this week. Klisyri® is a novel, topic
- Are Sunscreens Overstating Their SPF?https://practicaldermatology.com/news/are-sunscreens-overstating-their-spf/2460629/One out of 12 sunscreens worldwide are likely overstating their sun protection factor, according to research from What’s In My Jar, a London-based AI-powered skincare startup. Using machine learning, What’s In My Jar analyzed formulas of 1,205 sunscreen products in thei
- FDA Defers Approval of Revance's Toxin Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://practicaldermatology.com/news/fda-defers-approval-of-revances-toxin-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2460628/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r